Alembic Pharma gets USFDA nod for generic hypertension drug
New Delhi: Alembic Pharmaceuticals has received US health regulator's approval to market hypertension drug, candesartan cilexetil tablets, in the American market.
The company's product is therapeutically equivalent to AstraZeneca Pharmaceuticals' Atacand tablets which are indicated for treatment of hypertension, Alembic said in a regulatory filing.
As per IMS data, candesartan cilexetil tablets had an estimated market size of USD 27 million in the US market for twelve months ended December 2016.
Alembic now has a total of 57 abbreviated new drug application (ANDA) approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd